XML 59 R31.htm IDEA: XBRL DOCUMENT v3.22.0.1
Revenue (Tables)
 12 Months Ended
Dec. 31, 2021
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
The following table summarizes our revenue recognized in our consolidated statements of operations:
202120202019
Net product revenue$25,957.9 $22,694.8 $20,377.3 
Collaboration and other revenue(1)
2,360.5 1,845.0 1,942.2 
Revenue$28,318.4 $24,539.8 $22,319.5 
(1) Collaboration and other revenue associated with prior period transfers of intellectual property was $175.0 million, $135.6 million, and $301.5 million during the years ended December 31, 2021, 2020, and 2019, respectively.
The following table summarizes revenue by product:
U.S.Outside U.S.
202120202019202120202019
Revenue—to unaffiliated customers:
Diabetes:
Trulicity®
$4,914.4 $3,835.9 $3,155.2 $1,557.6 $1,232.2 $972.7 
Humalog® (1)
1,320.7 1,485.6 1,669.7 1,132.3 1,140.3 1,151.0 
Jardiance (2)
807.3 620.8 565.9 683.5 533.0 378.3 
Humulin®
832.9 866.4 879.7 389.6 393.2 410.4 
Basaglar®
588.3 842.3 876.2 304.2 282.1 236.3 
Trajenta (3)
82.1 95.6 224.8 290.4 263.0 365.8 
Other Diabetes173.6 162.5 158.0 111.2 81.5 88.1 
Total Diabetes8,719.3 7,909.1 7,529.5 4,468.8 3,925.3 3,602.6 
Oncology:
Alimta®
1,233.9 1,265.3 1,219.5 827.5 1,064.7 896.4 
Verzenio®
834.9 618.2 454.8 515.0 294.4 124.9 
Cyramza®
358.1 381.9 335.3 674.8 650.8 589.9 
Erbitux®
481.8 480.1 487.9 66.4 56.3 55.4 
Tyvyt®
— — — 418.1 308.7 134.0 
Other Oncology120.1 46.6 111.0 210.7 152.3 205.3 
Total Oncology3,028.8 2,792.1 2,608.5 2,712.5 2,527.2 2,005.9 
Immunology:
Taltz®
1,542.4 1,288.5 1,016.8 670.4 500.0 349.6 
Olumiant® (4)
324.1 63.8 42.2 791.0 575.0 384.7 
Other Immunology15.3 20.0 — 17.6 14.6 — 
Total Immunology1,881.8 1,372.3 1,059.0 1,479.0 1,089.6 734.3 
Neuroscience:
Cymbalta®
38.7 42.1 49.6 542.8 725.6 675.8 
Emgality®
434.5 325.9 154.9 142.7 37.0 7.7 
Zyprexa®
39.6 46.1 41.0 390.7 360.5 377.6 
Other Neuroscience102.0 73.2 111.0 207.5 220.9 305.3 
Total Neuroscience614.8 487.3 356.5 1,283.7 1,344.0 1,366.4 
Other:
COVID-19 Antibodies (5)
1,978.0 850.0 — 261.4 21.2 — 
Forteo®
441.6 510.3 645.5 360.3 536.0 759.1 
Cialis®
10.6 61.8 231.7 707.9 545.4 658.8 
Other136.1 246.4 291.9 233.9 321.8 469.7 
Total Other2,566.4 1,668.4 1,169.1 1,563.5 1,424.4 1,887.7 
Revenue$16,811.0 $14,229.3 $12,722.6 $11,507.4 $10,310.5 $9,596.8 
Numbers may not add due to rounding.
(1) Humalog revenue includes insulin lispro.
(2) Jardiance revenue includes Glyxambi®, Synjardy®, and Trijardy® XR.
(3) Trajenta revenue includes Jentadueto®.
(4) Olumiant revenue includes sales for baricitinib, for treatment in hospitalized COVID-19 patients, that were made pursuant to Emergency Use Authorization (EUA) or similar regulatory authorizations.
(5) COVID-19 antibodies include sales for bamlanivimab administered alone as well as sales for bamlanivimab and etesevimab administered together and were made pursuant to EUAs or similar regulatory authorizations.
The following table summarizes revenue by geographical area:
202120202019
Revenue—to unaffiliated customers(1):
U.S.$16,811.0 $14,229.3 $12,722.6 
Europe4,776.8 4,187.7 3,765.0 
Japan2,367.0 2,583.1 2,547.6 
China1,661.4 1,116.9 939.4 
Other foreign countries2,702.2 2,422.7 2,344.9 
Revenue$28,318.4 $24,539.8 $22,319.5 
Numbers may not add due to rounding.
(1) Revenue is attributed to the countries based on the location of the customer.
Schedule of Amounts Recorded for Contract Liabilities
The following table summarizes contract liability balances:
 20212020
Contract liabilities$262.6 $276.8